Drug combo aims to shield kidneys after cancer surgery
NCT ID NCT06818305
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 16 times
Summary
This study tested whether two medications, finerenone and empagliflozin, taken alone or together, could slow kidney function loss in people at high risk for chronic kidney disease after having a kidney removed due to cancer. Ten participants took the drugs daily for one year and had regular checkups. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing
Nanjing, Jiangsu, 210000, China
Conditions
Explore the condition pages connected to this study.